The Scottish Medicines Consortium (SMC) has approved Pfizer’s Bosulif (bosutinib) for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukaemia, within NHS Scotland. The treatment has been approved for patients who have previously been treated with one or more tyrosine kinase inhibitors, and for whom
Scotland’s regulatory advisory committee, the Scottish Medicines Consortium (SMC) have granted approval to Bristol-Myers Squibb’s Daklinza and Yervoy for use on the NHS in Scotland. Specifically, Daklinza (daclatasvir) received regulatory approval for use with other drugs for the treatment of chronic hepatitis C virus infection in adults. The approval grants access to Daklinza as a
The Scottish Medicines Consortium (SMC) has announced their latest set of recommendations approving regulatory submissions for Novartis and ThromboGenics’ eye therapy Jetrea and Roche’s RoActemra. The SMC have also announced rejections for the chronic obstructive pulmonary disease (COPD) drugs submitted for approval by Boehringer Ingelheim and GlaxoSmithKline (GSK).
Alimera Sciences yesterday announced that the Scottish Medicines Consortium (SMC) has approved Iluvien as a treatment for chronic diabetic macular oedema (DME) for restricted use within the NHS in the country. Use of Iluvien will be restricted to patients in whom the affected eye is pseudophakic, meaning that they have an artificial lens after cataract
Scottish regulatory body, the Scottish Medicines Consortium (SMC), have approved Roche’s MabThera (rituximab) for the National Health Service (NHS) in Scotland. MabThera has been approved to treat two potentially life-threatening illnesses, GPA and MPA.
